News

Under the terms of the agreement, Illumina will use Sentrix Arrays in conjunction with the company’s GoldenGate and Infinium assays to conduct genetic studies for thousands of samples

The drug did demonstrate effectiveness in the indication; however results from the trial showed that the amount of drug needed to achieve the desired anticoagulation for use in

Cystic Fibrosis Foundation Therapeutics, a nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, is supporting this trial with study-specific funding of up to $2.35 million

“The FDA’s Fast Track designation is a significant endorsement of the sizeable medical need for a product like MC-1,” commented Medicure’s president and CEO, Dr Albert Friesen. “The

Based on its discovery of a disease-causing molecule found only in the joints of RA patients, MaimoniDex has developed a murine monoclonal antibody that has shown bioactivities both

Lyrica has a newly defined mechanism of action and represents an important treatment advance. It is the first treatment approved by the FDA to treat two distinct forms

The first phase I trial will investigate the efficacy of XL844 in patients with chronic lymphocytic leukemia, the second trial for a compound labeled XL184 will be conducted

The two-year collaboration is the first ever to focus on developing a comprehensive disease management program which will focus on improved staging of the disease using both imaging

The partnership includes various agreements with regard to commercialization of Vitro’s stem cell lines for use in R&D and cross licenses to fertility drug technology and products owned